scholarly journals Lung-protective ventilation suppresses plasma levels of cell-free DNA in porcine experimental postoperative sepsis

Critical Care ◽  
2014 ◽  
Vol 18 (Suppl 1) ◽  
pp. P292 ◽  
Author(s):  
A Nyberg ◽  
J Sperber ◽  
M Lipcsey ◽  
J Jylhävä ◽  
M hurme ◽  
...  
2020 ◽  
Vol 20 (1) ◽  
Author(s):  
Axel Nyberg ◽  
Alexander Larsson ◽  
Juulia Jylhävä ◽  
Mikko Hurme ◽  
Jesper Sperber ◽  
...  

2019 ◽  
Author(s):  
Axel Nyberg ◽  
Alexander Larsson ◽  
Juulia Jylhävä ◽  
Mikko Hurme ◽  
Jesper Sperber ◽  
...  

Abstract Background: Plasma levels of cell-free DNA (cf-DNA) are known to be elevated in sepsis and high levels are associated with a poor prognosis. Mechanical ventilation affects systemic inflammation in which lung-protective ventilation attenuates the inflammatory response. Aim: To study the effect of tidal volume and PEEP on arterial and organ-specific venous blood as well as on trans-organ differences in cf-DNA levels in a porcine post-operative sepsis model. Method: One group of anaesthetised, domestic-breed, 9-12 weeks old, pigs were ventilated with protective ventilation (VT 6mL x kg-1, PEEP 10 cmH2O) n=20. Another group, ventilated with a medium high tidal volume and lower PEEP, served as a control group (VT 10 mL x kg-1, PEEP 5 cm H2O) n=10. Blood samples were taken from four sources: artery, hepatic vein, portal vein and, jugular bulb. A continuous endotoxin infusion at 0.25 µg x kg-1 x h-1 for 5 h was started following 2 h of laparotomy, which simulated a surgical procedure. Inflammatory cytokines and cf-DNA in plasma were analysed and trans-organ differences calculated. Results: The protective ventilation group had lower levels of cf-DNA in arterial (p=0.02) and hepatic venous blood (p=0.03) compared with the controls. Transhepatic differences in cf-DNA were lower in the protective group, compared with the controls (p=0.03). No differences between the groups were noted as regards the transcerebral, transsplanchnic or the transpulmonary cf-DNA differences. Conclusions: Protective ventilation suppresses arterial levels of cf-DNA. The liver seems to be a net contributor to the systemic cf-DNA levels, but this effect is attenuated by protective ventilation.


2020 ◽  
Vol 26 (4) ◽  
pp. 602-603
Author(s):  
Osamu Yoshino ◽  
Vijayaragavan Muralidharan ◽  
Alexander Dobrovic ◽  
Su Kah Goh

2005 ◽  
Vol 4 (3) ◽  
pp. 185
Author(s):  
F. Chun ◽  
I. Müller ◽  
K. Urban ◽  
M. Gottberg ◽  
L. Lange ◽  
...  
Keyword(s):  

2013 ◽  
Vol 305 (7) ◽  
pp. L455-L466 ◽  
Author(s):  
Sarah C. Christiaans ◽  
Brant M. Wagener ◽  
Charles T. Esmon ◽  
Jean Francois Pittet

The protein C system plays an active role in modulating severe systemic inflammatory processes such as sepsis, trauma, and acute respiratory distress syndrome (ARDS) via its anticoagulant and anti-inflammatory properties. Plasma levels of activated protein C (aPC) are lower than normal in acute inflammation in humans, except early after severe trauma when high plasma levels of aPC may play a mechanistic role in the development of posttraumatic coagulopathy. Thus, following positive results of preclinical studies, a clinical trial (PROWESS) with high continuous doses of recombinant human aPC given for 4 days demonstrated a survival benefit in patients with severe sepsis. This result was not confirmed by subsequent clinical trials, including the recently published PROWESS-SHOCK trial in patients with septic shock and a phase II trial with patients with nonseptic ARDS. A possible explanation for the major difference in outcome between PROWESS and PROWESS-SHOCK trials is that lung-protective ventilation was used for the patients included in the recent PROWESS-SHOCK, but not in the original PROWESS trial. Since up to 75% of sepsis originates from the lung, aPC treatment may not have added enough to the beneficial effect of lung-protective ventilation to show lower mortality. Thus whether aPC will continue to be used to modulate the acute inflammatory response in humans remains uncertain. Because recombinant human aPC has been withdrawn from the market, a better understanding of the complex interactions between coagulation and inflammation is needed before considering the development of new drugs that modulate both coagulation and acute inflammation in humans.


Sign in / Sign up

Export Citation Format

Share Document